Bactiguard Holding AB (FRA:5JE)

€ 3.12 0.36 (13.04%) Market Cap: 112.33 Mil Enterprise Value: 123.50 Mil PE Ratio: 0 PB Ratio: 3.82 GF Score: 61/100

Q3 2024 Bactiguard Holding AB Earnings Call Transcript
Oct 24, 2024

€3.81 (+1.33%)

Earnings
Q2 2024 Bactiguard Holding AB Earnings Call Transcript
Jul 16, 2024

€5.78 (+1.05%)

Earnings
Q4 2023 Bactiguard Holding AB Earnings Call Transcript
Feb 08, 2024

€6.11 (-10.93%)

Earnings
Q2 2023 Bactiguard Holding AB Earnings Call Transcript
Jul 18, 2023

€5.18 (-8.64%)

Earnings
Q1 2023 Bactiguard Holding AB Earnings Call Transcript
Apr 27, 2023

€5.74 (+0.17%)

Earnings
Q4 2022 Bactiguard Holding AB Earnings Call Transcript
Feb 09, 2023

€8.81 (-0.23%)

Earnings
Q3 2022 Bactiguard Holding AB Earnings Call Transcript
Oct 27, 2022

€9.18 (-2.24%)

Earnings
Q2 2022 Bactiguard Holding AB Earnings Call Transcript
Jul 14, 2022

€8.93 (-8.60%)

Earnings
Q1 2022 Bactiguard Holding AB Earnings Call Transcript
Apr 27, 2022

€11 (-2.31%)

Earnings
Q4 2021 Bactiguard Holding AB Earnings Call Transcript
Feb 09, 2022

€12.8 (-0.31%)

Earnings
Q3 2021 Bactiguard Holding AB Earnings Call Transcript
Oct 28, 2021

€15.86 (+0.38%)

Earnings
Bactiguard Holding AB Pareto Securities' Healthcare Conference 2021 Transcript
Sep 02, 2021
Q2 2021 Bactiguard Holding AB Earnings Call Transcript
Jul 15, 2021

€18.6 (-0.96%)

Earnings
Bactiguard Holding AB Nordic Mid Small Cap Seminar 2021 Transcript
Jun 02, 2021
Q1 2021 Bactiguard Holding AB Earnings Call Transcript
Apr 22, 2021

€18.58 (+3.45%)

Earnings
Q3 2020 Bactiguard Holding AB Earnings Call Transcript
Nov 05, 2020

€14.85 (+3.48%)

Earnings
Q2 2020 Bactiguard Holding AB Earnings Call Transcript
Aug 13, 2020

€17.1 (+0.29%)

Earnings

Q4 2021 Bactiguard Holding AB Earnings Call Transcript

Feb 09, 2022 / 02:00PM GMT

Release Date Price: €12.8 (-0.31%)

Transcript

Anders GÃ;ransson;publ;CEO

Bactiguard Holding AB

¶ - ()-

And thank you, everybody, for joining the call today, in which we will share some very exciting news and forward-looking thinking from our side.

Before we start, I want to inform you that a correction to our quarter-four press release. As we wanted you to have all relevant information at your hand, when we announced the Zimmer Biomet agreement last night, we accelerated our quarterly release, and we released it already last night. However, due to human factor, we released some incorrect numbers relating to the cash flow from operating activities.

We have, therefore, just released the corrected version, both in English and Swedish. Furthermore, this morning, it was noticed that the Swedish version still included some internal working comments that had been fully integrated in the report. Of course, this is not something we're proud of, and we're very sorry for this. And we are revising our processes to increase the quality, going forward.

If we go to page 2 and the more

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.